News Category
Quantum BioPharma has signed a Study Start-Up Agreement with Thermo Fisher Scientific's clinical research business to execute a Phase 2 trial of Lucid...
Quantum BioPharma has signed a Study Start-Up Agreement with Thermo Fisher Scientific's clinical research business to implement a Phase 2 trial of Luc...
Quantum BioPharma's agreement with Thermo Fisher's clinical research business moves its novel myelin-protective multiple sclerosis drug Lucid-MS into ...
XORTX Therapeutics is advancing XORLO, a proprietary oxypurinol formulation, toward an FDA new drug application, aiming to address the growing need fo...
In vitro ADME studies are critical for early drug candidate assessment, improving success rates and reducing costs in pharmaceutical development.
A new study reveals that the risk of sepsis, meningitis, or pneumonia from air pollution depends on individual bacterial strains, highlighting the nee...
Peptide Wholesale Supply has expanded its HPLC verification protocols to bulk orders of BPC-157, Semaglutide, and Tirzepatide, providing batch-specifi...
Incorporating clinical trial discussions into the initial appointment for small cell lung cancer can provide patients with timely access to emerging t...
GeoVax's agreement with CEPI to use its Centralised Laboratory Network for the Phase 3 trial of GEO-MVA aims to provide independent validation and div...
Tevard Biosciences and collaborators published preclinical research in Science Advances demonstrating that engineered suppressor tRNAs can restore ful...
Creative Biolabs has expanded its functionalized lipid-based delivery system capabilities to help researchers overcome stability, targeting, and contr...
BioCorRx Inc. appointed Richard J. Baum, former Acting Director of the White House Office of National Drug Control Policy, to its Strategic Advisory B...
Regentis Biomaterials reports progress in its Phase III GelrinC trial for knee cartilage repair and receives European approval for a manufacturing pro...
Quantum BioPharma's Lucid-MS, a first-in-class drug that protects and rebuilds myelin, has received FDA clearance for a Phase 2 trial that could trans...
Regentis Biomaterials is developing GelrinC, an off-the-shelf hydrogel implant that supports cartilage regeneration, offering a potential alternative ...
VERAXA Biotech's appointment of Dr. Christoph Erkel as chief scientific officer strengthens its leadership as it advances its BiTAC® T-cell engager an...
Quantum BioPharma's FDA clearance for a phase 2 trial of Lucid-MS, a first-in-class myelin-repair therapy, could transform the multibillion-dollar mul...
Quantum BioPharma's Lucid-MS, a first-in-class PAD2 inhibitor, has received FDA clearance to begin a Phase 2 trial for multiple sclerosis, potentially...
Quantum BioPharma's FDA clearance for a phase 2 trial of Lucid-MS represents a historic first in multiple sclerosis treatment, potentially unlocking a...
Helus Pharma's CEO will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference, highlighting the company's advanced clinica...
Onco-Innovations' CMO detailed the company's novel PNKP-targeting drug candidate ONC010, which uses synthetic lethality and nanoparticle delivery to p...
Quantum BioPharma's Lucid-MS, a first-in-class non-covalent PAD2 inhibitor, has received FDA clearance to begin a Phase 2 trial in multiple sclerosis,...
An expert highlights the overlooked shortcomings in UTI diagnosis, emphasizing the need for advanced tools to address recurrent infections and their i...
Silo Pharma's participation in the IPAC-RS 2026 Nasal Innovation Forum underscores its commitment to advancing SPC-15, a nose-to-brain therapy for PTS...
Quantum BioPharma's FDA clearance to advance Lucid-MS into Phase 2 trials marks a significant milestone for a novel myelin-repair approach to multiple...
Quantum BioPharma's multiple sclerosis drug candidate Lucid-MS has received FDA clearance to begin a Phase 2 trial, a rare milestone for a micro-cap b...
GeoVax applauds the new global mpox vaccine stockpile and highlights its GEO-MVA candidate's readiness to support a diversified supply.
VERAXA Biotech's appointment of Raju Willener as CFO signals a strategic move to enhance its capital strategy and support the advancement of its oncol...
Scinai Immunotherapeutics has strategically exited its PC111 license with PinCell to concentrate resources on its NanoAb platform and CDMO business, a...
Onco-Innovations Ltd. strengthens its clinical foundation for ONC010, a nanoparticle-encapsulated PNKP inhibitor, through manufacturing milestones, IN...
Quantum BioPharma's FDA clearance for a Phase 2 trial of Lucid-MS, a first-in-class myelin repair candidate, marks a pivotal step toward treating the ...
A new study from Washington University School of Medicine highlights the growing role of laser interstitial thermal therapy (LITT) in treating brain c...
Ocumetics Technology Corp. has initiated patient recruitment for the Group Two human clinical study of its next-generation accommodating intraocular l...
Quantum BioPharma's FDA clearance for a phase 2 trial of Lucid-MS marks a potential breakthrough in treating multiple sclerosis by targeting myelin re...
NanoViricides' registration of its Phase II Ebola trial in the DRC marks a critical step in evaluating NV-387 as a potential treatment for Ebola, with...
The FDA has cleared Quantum BioPharma's IND application to begin a Phase 2 trial of Lucid-MS in multiple sclerosis, a key milestone for the first-in-c...
Quantum BioPharma's FDA clearance for a Phase 2 trial of Lucid-MS, a novel remyelination agent, marks a significant step in MS treatment and draws ana...
Quantum BioPharma's FDA clearance to initiate a Phase 2 trial of Lucid-MS marks a pivotal step toward a novel therapy for multiple sclerosis that targ...
Tonix Pharmaceuticals elevates Thomas Englese to Chief Commercial Officer to lead commercialization efforts for its fibromyalgia treatment TONMYA and ...
A large study reveals that the timing of brain metastasis development significantly impacts survival in colorectal cancer patients, underscoring the n...
Onco-Innovations has achieved significant preclinical milestones for its PNKP inhibitor ONC010, including high-purity API production and an Australian...
OS Therapies' participation at the Moody Capital conference comes as it approaches key FDA and U.K. regulatory decisions and data readouts for its lea...
A Swiss-led preclinical study reveals that administering immunotherapy prior to surgical resection significantly improves glioblastoma treatment outco...
The FDA's failure to enforce laws against the illegal online sale of retatrutide has allowed a dangerous black market to flourish, endangering consume...
New research from Mass General Brigham reveals that unintended radiation to the thymus during lung cancer treatment is associated with poorer clinical...
Tonix Pharmaceuticals' participation in the Cantor 2026 Global Healthcare Conference highlights its strategic focus on CNS and immunology advancements...
NurExone Biologic's participation in the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference highlights its advancing exosome-ba...
CNS Pharmaceuticals' Chief Business Officer details the company's focus on in-licensing and acquiring oncology and neurology assets to build a pipelin...
